Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study

By sjmartinez • January 26, 2025

Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne AM, Cotter C, Badhrinarayanan S, Wang Y, Yin A, Edubilli TR, Mahrus S, Secrest MH, Shemesh CS, Yu N, Hack SP, Cha E, Gane E. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study. Lancet Oncol. 2025 Jan 21:S1470-2045(24)00679-X. doi: 10.1016/S1470-2045(24)00679-X. Epub ahead of print. PMID: 39855251.

Tags: Hematology/Oncology, Publications

Paraneoplastic Trichomegaly as a Harbinger of Metastatic Renal Cell Carcinoma: A Case Report

Reichl A, Callahan R. Paraneoplastic Trichomegaly as a Harbinger of Metastatic Renal Cell Carcinoma: A Case Report. Cureus. 2025 May 6;17(5):e83550. doi: 10.7759/cureus.83550. PMID: 40476135;[...]

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Lucas PC, Gupta N, Li[...]

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Riess JW, de Langen AJ, Ponce S, Goldberg SB, Piotrowska Z, Goldman JW, Le X, Cho BC, Yoneshima Y, Ambrose H, Cavazzina R, Tang KH,[...]